BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 31768066)

  • 1. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
    Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
    Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
    Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
    Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
    Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
    Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring.
    Zviran A; Schulman RC; Shah M; Hill STK; Deochand S; Khamnei CC; Maloney D; Patel K; Liao W; Widman AJ; Wong P; Callahan MK; Ha G; Reed S; Rotem D; Frederick D; Sharova T; Miao B; Kim T; Gydush G; Rhoades J; Huang KY; Omans ND; Bolan PO; Lipsky AH; Ang C; Malbari M; Spinelli CF; Kazancioglu S; Runnels AM; Fennessey S; Stolte C; Gaiti F; Inghirami GG; Adalsteinsson V; Houck-Loomis B; Ishii J; Wolchok JD; Boland G; Robine N; Altorki NK; Landau DA
    Nat Med; 2020 Jul; 26(7):1114-1124. PubMed ID: 32483360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for Measuring ctDNA in Lymphomas.
    Rossi D; Condoluci A; Spina V; Gaidano G
    Methods Mol Biol; 2019; 1881():253-265. PubMed ID: 30350211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.
    Willis J; Lefterova MI; Artyomenko A; Kasi PM; Nakamura Y; Mody K; Catenacci DVT; Fakih M; Barbacioru C; Zhao J; Sikora M; Fairclough SR; Lee H; Kim KM; Kim ST; Kim J; Gavino D; Benavides M; Peled N; Nguyen T; Cusnir M; Eskander RN; Azzi G; Yoshino T; Banks KC; Raymond VM; Lanman RB; Chudova DI; Talasaz A; Kopetz S; Lee J; Odegaard JI
    Clin Cancer Res; 2019 Dec; 25(23):7035-7045. PubMed ID: 31383735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
    Rose Brannon A; Jayakumaran G; Diosdado M; Patel J; Razumova A; Hu Y; Meng F; Haque M; Sadowska J; Murphy BJ; Baldi T; Johnson I; Ptashkin R; Hasan M; Srinivasan P; Rema AB; Rijo I; Agarunov A; Won H; Perera D; Brown DN; Samoila A; Jing X; Gedvilaite E; Yang JL; Stephens DP; Dix JM; DeGroat N; Nafa K; Syed A; Li A; Lebow ES; Bowman AS; Ferguson DC; Liu Y; Mata DA; Sharma R; Yang SR; Bale T; Benhamida JK; Chang JC; Dogan S; Hameed MR; Hechtman JF; Moung C; Ross DS; Vakiani E; Vanderbilt CM; Yao J; Razavi P; Smyth LM; Chandarlapaty S; Iyer G; Abida W; Harding JJ; Krantz B; O'Reilly E; Yu HA; Li BT; Rudin CM; Diaz L; Solit DB; Arcila ME; Ladanyi M; Loomis B; Tsui D; Berger MF; Zehir A; Benayed R
    Nat Commun; 2021 Jun; 12(1):3770. PubMed ID: 34145282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
    van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
    Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
    Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
    J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
    Schweizer MT; Gulati R; Beightol M; Konnick EQ; Cheng HH; Klemfuss N; De Sarkar N; Yu EY; Montgomery RB; Nelson PS; Pritchard CC
    Prostate; 2019 May; 79(7):701-708. PubMed ID: 30865311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
    Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
    BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients.
    Koeppel F; Blanchard S; Jovelet C; Genin B; Marcaillou C; Martin E; Rouleau E; Solary E; Soria JC; André F; Lacroix L
    PLoS One; 2017; 12(11):e0188174. PubMed ID: 29161279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using plasma cell-free DNA to monitor the chemoradiotherapy course of cervical cancer.
    Tian J; Geng Y; Lv D; Li P; Cordova M; Liao Y; Tian X; Zhang X; Zhang Q; Zou K; Zhang Y; Zhang X; Li Y; Zhang J; Ma Z; Shao Y; Song L; Owen GI; Li T; Liu R; Liu Q; Zou L; Zhang Z; Li Z
    Int J Cancer; 2019 Nov; 145(9):2547-2557. PubMed ID: 30919951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragmentation patterns of cell-free DNA and somatic mutations in the urine of metastatic breast cancer patients.
    Lin S; Wang S; Xu B
    J Cancer Res Ther; 2024 Apr; 20(2):563-569. PubMed ID: 38454812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.